Complete Guide to SARMs UK: Research Compounds Explained for 2026

SARMs UK searches now cover a complicated market containing genuine selective androgen receptor modulators, growth-hormone secretagogues, REV-ERB agonists, PPARδ agonists and several experimental compounds with different mechanisms and levels of scientific evidence.

This creates an important classification problem.

RAD-140 Testolone, LGD-4033 Ligandrol, Ostarine MK-2866, S-4 Andarine, S-23, AC-262 and ACP-105 are associated with androgen-receptor research. MK-677 Ibutamoren is a ghrelin-receptor agonist and growth-hormone secretagogue. Cardarine GW-501516 is a PPARδ agonist. SR-9009 and SR-9011 are investigated through REV-ERB pathways.

These compounds may appear together in SARMs collections because that is how the wider research-compound market categorises them, but they should not be described as scientifically identical.

A trustworthy SARMs UK guide must therefore do more than rank products or repeat promotional claims. It should explain what qualifies as a genuine SARM, how androgen-receptor selectivity is investigated, which compounds have published research, where the evidence remains preliminary and what researchers should check when comparing UK SARMs suppliers.

This BioPlex Peptides guide examines SARMs capsules, compound classification, research evidence, UK supply, product testing, certificates of analysis, laboratory documentation and responsible research-only presentation in 2026.

It does not provide personal-use instructions, dose recommendations, cycles, stacking protocols or performance-enhancement guidance.

What Does SARM Mean?

SARM stands for selective androgen receptor modulator.

The androgen receptor is a nuclear receptor activated by androgens and other compatible molecular ligands. Once activated, it can influence the transcription of genes involved in tissue development, protein regulation, cellular differentiation, skeletal-muscle biology, bone signalling and reproductive physiology.

A selective androgen receptor modulator is designed to interact with this receptor while producing different levels of activity across separate tissues.

The scientific objective is not necessarily to create a compound that activates the androgen receptor in only one location. Instead, researchers investigate whether a ligand can produce a different balance of receptor activity, gene transcription and cofactor recruitment from conventional steroidal androgens.

This distinction is important because selective does not mean completely isolated, universally safe or active only within skeletal-muscle models.

Selectivity can depend on:

Chemical structure
Receptor-binding affinity
Ligand concentration
Tissue distribution
Cellular environment
Coactivator and corepressor availability
Metabolic conversion
Exposure duration
Gene-expression context
Experimental model

Two SARMs may bind to the same receptor but produce different receptor conformations and transcriptional responses.

This is why SARMs research cannot be reduced to a simple strongest-to-weakest ranking.

How Do SARMs Work in Research?

Many non-steroidal SARMs are small molecules capable of entering androgen-responsive cells and interacting with the androgen receptor.

Before ligand binding, the androgen receptor is generally located within the cytoplasm in association with heat-shock proteins and other regulatory components.

When a compatible SARM binds to the receptor, several connected events may occur:

The ligand changes the receptor’s three-dimensional conformation.
Regulatory proteins associated with the receptor are rearranged or released.
The activated receptor-ligand complex translocates into the nucleus.
The complex interacts with androgen-response elements associated with DNA.
Coactivator and corepressor proteins influence the resulting transcriptional response.
The expression of selected androgen-responsive genes may change.

The precise response depends on the compound and experimental environment.

Researchers may examine endpoints involving:

Androgen-receptor binding
Receptor activation
Nuclear translocation
Gene transcription
Myogenic differentiation
Protein turnover
Lean-tissue measurements
Bone-associated signalling
Cellular proliferation
Nitrogen-related endpoints
Coactivator recruitment
Tissue-selective activity

The phrase tissue selective describes a relative experimental pattern. It should not be interpreted as proof that a compound has no activity outside the principal tissue being investigated.

Why Were SARMs Developed?

SARMs were developed to investigate whether androgen-receptor activity could be separated more effectively across different tissues.

Traditional steroidal androgens can produce broad activity throughout androgen-responsive systems. Researchers wanted to determine whether non-steroidal receptor ligands could preserve selected anabolic signalling while reducing activity associated with other tissues.

Potential research areas have included:

Muscle-wasting models
Age-associated tissue loss
Cancer-associated cachexia
Bone-density research
Osteoporosis-related pathways
Functional-performance endpoints
Recovery from immobilisation
Androgen-receptor-positive disease models

Several compounds progressed into preclinical or clinical research, but evidence and development status vary substantially.

No SARM has achieved general approval as a medicine for personal consumption. Some development programmes were discontinued, some produced mixed functional outcomes and others remain investigational.

A compound reaching a clinical trial does not establish that online products sold under the same name are approved medicines or equivalent to the material evaluated in controlled studies.

Which Compounds Are Genuine SARMs?

A genuine SARM should interact with the androgen receptor and demonstrate some form of selective androgen-receptor modulation.

Compounds commonly classified as SARMs include:

RAD-140 Testolone
LGD-4033 Ligandrol
Ostarine MK-2866
S-4 Andarine
S-23
AC-262,536 Accadrine
ACP-105
RAD-150 TLB-150
YK-11, although its steroidal structure and partial-agonist profile require additional explanation

These compounds should not automatically be treated as equivalent.

Some are non-steroidal receptor ligands. YK-11 is structurally steroidal. Some have published clinical evidence, while others are supported mainly by laboratory or preclinical studies.

The complete evidence should be considered before comparing compounds.

RAD-140 Testolone Research

RAD-140, also called Testolone and vosilasarm, is a non-steroidal selective androgen receptor modulator.

It was developed as a potent androgen-receptor ligand and has been investigated across several experimental areas, including tissue-selective androgen signalling, neural models and androgen-receptor-positive disease research.

RAD-140 binds to the androgen receptor and can influence androgen-responsive gene transcription. Preclinical studies have examined its activity within skeletal, reproductive and neural tissues.

Its scientific profile is broader than the muscle-related claims commonly repeated online. Research has included cultured cellular systems, animal models and early clinical investigation in specialised disease settings.

However, the published evidence does not establish RAD-140 as an approved medicine or support the certainty suggested by many commercial rankings.

Researchers comparing RAD-140 UK products should separate documented receptor activity from unsupported claims about guaranteed outcomes.

View RAD-140 Testolone Research Capsules at BioPlex Peptides ⟶

LGD-4033 Ligandrol Research

LGD-4033, commonly known as Ligandrol, is a non-steroidal SARM with high androgen-receptor affinity.

LGD-4033 has a stronger published clinical-research footprint than many compounds grouped within the SARMs market.

A placebo-controlled investigation examined LGD-4033 across several experimental concentrations over 21 days. Researchers assessed pharmacokinetics, lean-tissue measurements, hormone-related markers and other biological endpoints.

The study produced concentration-dependent changes in selected measurements, but short-duration research cannot answer every question involving extended exposure, broader safety or functional outcomes.

LGD-4033 illustrates why evidence should be assessed in layers:

Receptor binding demonstrates molecular interaction.
Cellular studies examine intracellular responses.
Animal studies examine activity across complete biological systems.
Early clinical studies evaluate selected measurements under controlled conditions.
Longer and larger studies are required to establish wider conclusions.

Ligandrol should therefore be described as a genuine SARM with meaningful published evidence, but not as an approved or universally established compound.

View LGD-4033 Ligandrol Research Capsules at BioPlex Peptides ⟶

Ostarine MK-2866 Research

Ostarine is also known as Enobosarm, GTx-024, MK-2866 and S-22.

It is one of the most extensively studied selective androgen receptor modulators and has appeared in multiple investigations involving lean-tissue measurements, physical-function endpoints and muscle-wasting research.

Some controlled studies reported changes in lean-body-mass measurements. However, changes in tissue quantity should not automatically be interpreted as proportional improvements in strength, functional performance or long-term safety.

Different trials have also produced different results depending on:

Study population
Experimental duration
Selected concentration
Baseline condition
Primary endpoint
Measurement method
Statistical design

Ostarine is a valuable example of why research evidence should not be simplified into marketing language. It has a more developed evidence base than many newer SARMs, but it has not received general medicine approval.

Researchers searching for Ostarine UK or MK-2866 research compounds should look for correct naming because online listings may also use MK-2688 incorrectly.

View Ostarine MK-2866 Research Capsules at BioPlex Peptides ⟶

S-4 Andarine Research

S-4 is commonly called Andarine and has also been associated with the experimental code GTx-007.

It is a non-steroidal androgen-receptor ligand investigated during the earlier development of tissue-selective androgen receptor modulators.

Research has examined androgenic and anabolic activity, tissue selectivity and receptor-mediated signalling. Much of the evidence originates from preclinical rather than large controlled clinical studies.

S-4 remains a genuine SARM by mechanism, but its evidence profile should be distinguished from the published data surrounding Ostarine or LGD-4033.

A supplier should not present every SARM as though it has undergone the same level of research.

View S-4 Andarine Research Capsules at BioPlex Peptides ⟶

S-23 Research

S-23 is a non-steroidal selective androgen receptor modulator studied for high-affinity androgen-receptor activity.

Its research has focused largely on preclinical models examining androgen-responsive tissue, reproductive signalling and anabolic-to-androgenic activity patterns.

S-23 is sometimes positioned online using definitive strength or performance claims. The evidence does not justify reducing its scientific profile to those descriptions.

Researchers should consider:

The experimental model
Species differences
Selected endpoint
Exposure conditions
Receptor-binding data
Lack of general regulatory approval

S-23 is correctly classified as a SARM, but its public evidence base remains more limited than that of Ostarine or LGD-4033.

View S-23 Mastorin Research Capsules at BioPlex Peptides ⟶

AC-262 Accadrine Research

AC-262,536, commonly shortened to AC-262 and called Accadrine, is an androgen-receptor modulator associated with partial-agonist research.

A partial agonist can activate a receptor while producing a lower maximal response than a full agonist under the same experimental conditions.

This does not automatically make a compound weak, safe or predictable. Partial-agonist behaviour can vary according to receptor density, tissue type, competing ligands and intracellular signalling conditions.

AC-262 has a smaller published evidence base than established clinical-development compounds such as Ostarine and LGD-4033.

It remains relevant to SARMs research because it allows researchers to examine how different ligand structures and activation profiles affect androgen-receptor signalling.

View AC-262 Accadrine Research Capsules at BioPlex Peptides ⟶

ACP-105 Research

ACP-105 is another non-steroidal androgen-receptor modulator investigated for tissue-selective activity.

Available research has examined receptor binding, anabolic signalling and activity across selected preclinical models.

Its public research footprint is smaller than those of Ostarine and LGD-4033. This makes responsible evidence grading particularly important.

Researchers should not assume that a newer or less extensively studied compound represents an improved version of an established SARM. Novelty indicates limited accumulated evidence—not automatic scientific superiority.

Explore ACP-105 Androxepen and Other BioPlex SARMs ⟶

RAD-150 TLB-150 Research

RAD-150 is commonly called TLB-150 and is generally described as a chemically modified derivative associated with RAD-140.

The addition of a benzoate-related structural feature differentiates RAD-150 from RAD-140. This means the compounds should not be treated as identical simply because they share the RAD naming convention.

RAD-150 has a substantially smaller public research footprint than RAD-140. Claims concerning extended activity or improved performance should therefore be treated cautiously unless supported by compound-specific analytical and pharmacokinetic evidence.

Researchers comparing RAD-140 vs RAD-150 should examine chemical identity, molecular weight, structure, batch documentation and the evidence available for each individual compound.

View RAD-150 TLB-150 Research Capsules at BioPlex Peptides ⟶

Is YK-11 a Genuine SARM?

YK-11 is commonly marketed and discussed as a SARM, but its classification requires more precision.

Unlike widely recognised non-steroidal SARMs such as RAD-140, LGD-4033 and Ostarine, YK-11 has a steroidal molecular structure.

Laboratory research has described YK-11 as an androgen-receptor partial agonist. Preliminary cellular studies have also examined its relationship with myogenic differentiation and follistatin expression.

These findings have created substantial online interest, but YK-11 does not have the same evidence base as better-studied non-steroidal SARMs.

Important limitations include:

A narrow published literature
Strong dependence on cellular models
Limited controlled clinical evidence
Uncertainty when translating preliminary molecular findings
Frequent overstatement within commercial content

YK-11 belongs within androgen-receptor research discussion, but it should be described as a structurally steroidal partial agonist rather than treated as scientifically identical to RAD-140 or LGD-4033.

View YK-11 Myostine Research Capsules at BioPlex Peptides ⟶

Which Products Sold as SARMs Are Not Genuine SARMs?

The commercial SARMs category is broader than the scientific definition.

Products are frequently grouped together because customers search for them together, not because they share the same molecular target.

Common examples include:

MK-677 Ibutamoren
Cardarine GW-501516
SR-9009 Stenabolic
SR-9011
MK-777 Acetamoren

These compounds should be separated by mechanism.

Why MK-677 Ibutamoren Is Not a SARM

MK-677 is commonly sold and searched within the SARMs UK market, but it does not principally act through the androgen receptor.

MK-677 is more accurately classified as a ghrelin-receptor agonist and growth-hormone secretagogue.

Its principal molecular target is growth-hormone secretagogue receptor 1a, commonly abbreviated as GHSR-1a.

Research has examined relationships involving:

Ghrelin-receptor signalling
Growth-hormone secretion
IGF-1-associated markers
Endocrine regulation
Metabolic endpoints
Body-composition measurements
Sleep-related experimental variables

MK-677 should therefore not be compared with RAD-140 or LGD-4033 as though all three compounds use the same pathway.

It is included within many SARMs collections because of established search and market behaviour.

Read Is MK-677 a SARM? Ibutamoren Explained ⟶

View MK-677 Ibutamoren Research Capsules at BioPlex Peptides ⟶

Why Cardarine GW-501516 Is Not a SARM

Cardarine, also known as GW-501516, is not an androgen-receptor modulator.

It is associated with peroxisome proliferator-activated receptor delta, commonly abbreviated as PPARδ.

Research has examined PPARδ-related pathways involving:

Lipid metabolism
Fatty-acid oxidation
Energy regulation
Mitochondrial activity
Metabolic gene expression
Endurance-related experimental models

These mechanisms are different from androgen-receptor signalling.

The phrase Cardarine SARM remains a common search term, but Cardarine should be classified as a PPARδ agonist rather than a selective androgen receptor modulator.

Why SR-9009 and SR-9011 Are Not SARMs

SR-9009 and SR-9011 are experimental compounds associated with REV-ERB receptor research.

REV-ERB proteins participate in circadian regulation, metabolic gene expression and energy-related signalling.

Research involving SR-9009 and SR-9011 has examined:

Circadian pathways
Metabolic regulation
Mitochondrial endpoints
Energy-expenditure models
Lipid and glucose-associated variables
Skeletal-muscle metabolic signalling

These compounds do not principally work through the androgen receptor and should not be classified as genuine SARMs.

Their inclusion in SARMs collections reflects wider commercial categorisation rather than molecular classification.

SARMs vs Anabolic Steroids

SARMs and anabolic-androgenic steroids can both interact with the androgen receptor, but they are not chemically identical.

Many traditional anabolic steroids share the steroid nucleus and can undergo metabolism involving enzymes such as aromatase or 5α-reductase, depending on the compound.

Many established SARMs are non-steroidal molecules designed to investigate different receptor conformations and tissue-selective transcriptional activity.

The main research distinction is not that one category activates the androgen receptor and the other does not. Both can influence androgen-receptor pathways.

The distinction concerns:

Molecular structure
Receptor conformation
Cofactor recruitment
Tissue-selective activity
Metabolism
Pharmacokinetics
Gene-expression patterns
Evidence and development history

SARMs should not be described as automatically safe alternatives to anabolic steroids. Tissue selectivity is a research objective, not proof of zero activity or risk outside a selected tissue.

What Does Published SARMs Research Actually Show?

The evidence supporting SARMs varies by compound and experimental stage.

Researchers should distinguish among:

Receptor-binding studies

These investigations examine whether a compound binds to the androgen receptor and with what apparent affinity.

Binding does not prove a complete biological outcome.

Cellular research

Cellular models can examine receptor activation, gene transcription, protein expression, myogenic differentiation and related molecular responses.

Results remain dependent on the selected cell line, concentration and laboratory conditions.

Preclinical research

Animal models allow researchers to examine distribution and activity across complete biological systems.

Species differences can limit direct translation.

Early clinical research

Phase 1 and Phase 2 studies may investigate pharmacokinetics, tolerability and selected biological endpoints.

Short studies involving small populations cannot establish every long-term outcome.

Later-stage clinical research

Larger trials can provide stronger evidence, but results still depend on trial design, selected population and endpoints.

A compound may change a tissue measurement without producing the expected functional improvement.

The most responsible interpretation considers the complete evidence hierarchy rather than selecting one favourable result.

Are SARMs Approved in the UK?

SARMs remain experimental compounds and are not generally authorised as medicines for personal consumption.

UK Anti-Doping states that no SARM has been approved for personal consumption by an official medicines or healthcare-products regulator.

The Food Standards Agency considers SARMs to be unauthorised novel foods. They cannot lawfully be sold or advertised as foods or dietary supplements in the UK.

Research-only supply must also be genuine. A disclaimer does not automatically override surrounding advertising, product presentation, personal-use guidance or distribution practices indicating another intended purpose.

A responsible UK SARMs supplier should avoid:

Personal dose instructions
Cycle guidance
Stacking protocols for personal use
Treatment claims
Transformation promises
Before-and-after marketing
Influencer-led performance claims
Claims that SARMs are approved supplements
Claims that research-only wording removes every regulatory obligation

BioPlex Peptides presents its SARMs and related compounds for laboratory research, analytical investigation and educational reference only.

Are SARMs Prohibited in Sport?

Yes. SARMs are included within the World Anti-Doping Agency Prohibited List under anabolic agents.

They are prohibited at all times, including during and outside competition.

Examples named within anti-doping guidance include:

Ostarine
LGD-4033
RAD-140
S-4
S-23
AC-262
ACP-105
YK-11

Athletes remain responsible for substances found in their samples, including undeclared ingredients within contaminated or incorrectly labelled supplements.

Research-only labelling does not make a prohibited substance acceptable within regulated sport.

Anyone subject to anti-doping rules should avoid handling or exposure without appropriate institutional controls and should consult official anti-doping guidance relevant to their position.

What Does “Research Use Only” Mean?

Research-use-only wording should describe the genuine intended purpose of the product.

A responsible research supplier should focus on:

Chemical identity
Molecular classification
Batch information
Analytical purity
Laboratory documentation
Storage requirements
Experimental pathways
Evidence quality
Research limitations

Research-only wording becomes less credible when a supplier also provides personal-use instructions, cycles, transformation claims or advice designed around individual consumption.

The complete website matters—not just the disclaimer at the bottom of one product page.

BioPlex supports a research-focused approach by providing scientific articles, product specifications, testing information, company details, compliance pages and clear legal notices.

Why SARMs Testing Matters

The identity printed on a bottle does not prove what the capsules contain.

Reliable SARMs research depends on establishing:

Compound identity
Purity
Quantity
Batch consistency
Contamination profile
Documentation traceability

Several analytical methods may contribute different information.

HPLC analysis

High-performance liquid chromatography can separate components within a sample and estimate chromatographic purity.

An HPLC purity result does not independently prove the identity of every peak.

Mass-spectrometry analysis

Mass spectrometry can provide information concerning molecular mass and support compound identification.

Identity and purity are related but separate analytical questions.

Quantity analysis

A sample may contain the correct compound at high purity while containing a different quantity from the label claim.

Researchers should therefore distinguish among:

Identity testing
Purity testing
Quantity testing
Contaminant screening
Microbiological testing
Batch consistency

A single percentage displayed on a certificate does not answer every quality question.

How to Read a SARMs Certificate of Analysis

A useful certificate of analysis should be connected to the actual product batch.

Researchers should check:

Product name
Compound identity
Batch or lot number
Date of analysis
Testing method
Purity result
Laboratory identity
Sample reference
Chromatogram or spectrum where available
Whether quantity was tested separately
Whether the certificate matches the current stock

Warning signs include:

No batch number
No analytical date
A report reused across different products
A certificate referring to raw powder when the finished capsule is materially different
Cropped or unreadable documentation
No laboratory identity
A purity claim without a stated analytical method
Reports that cannot be connected to current inventory

Certificates should support supplier transparency, but they should not be treated as automatic proof of every quality characteristic.

What Should Researchers Check Before Buying SARMs UK?

Searches including buy SARMs UK, SARMs for sale UK, research SARMs UK and SARMs capsules UK show strong interest in supplier comparison.

Before selecting a research supplier, customers should check more than prices and product photographs.

Important trust signals include:

Visible company identity

The website should identify the business responsible for operating it.

Researchers should be able to check the registered company name, company number, contact routes and legal pages.

Batch-specific product information

Product listings should identify the compound, format, stated strength and available batch documentation.

Testing transparency

The supplier should explain what testing has been completed, which method was used and whether the result relates to purity, identity or quantity.

Responsible product descriptions

Content should explain scientific classification and limitations without providing personal-use protocols.

Accurate categorisation

A trustworthy supplier should acknowledge when MK-677, Cardarine, SR-9009 or SR-9011 are commercially grouped with SARMs despite using different mechanisms.

Stable customer support

Customers should have access to established contact routes rather than relying solely on social-media messages.

Legal and privacy information

Terms and conditions, privacy information, research-use notices and company details should be easy to locate.

Product consistency

Capsule strength, labelling and batch references should be clear across the range.

Read How to Choose a SARMs Supplier in the UK ⟶

BioPlex SARMs Capsules UK

BioPlex Peptides supplies a dedicated UK SARMs capsule collection containing genuine SARMs and related research compounds.

The current range includes more than a dozen capsule products covering androgen-receptor, ghrelin-receptor and REV-ERB-related research categories.

BioPlex sources selected raw SARMs powders and arranges UK capsule production to chosen specifications. This supports greater control over:

Capsule strength
Capsule presentation
Colour coding
Product identity
Batch organisation
Label consistency
Finished-product documentation

Many BioPlex SARMs products are supplied as 50-capsule research formats, with selected products listed at 15mg per capsule.

These format details do not replace analytical verification, but they support clearer product comparison and consistent research documentation.

BioPlex also provides access to independent analytical testing through its relationship with Vanguard Laboratory. Researchers should select the appropriate testing method according to whether they need identity, purity, quantity or broader analytical information.

Explore Independent Testing Through Vanguard Laboratory ⟶

Frequently Asked Questions About SARMs UK

What are SARMs?

SARMs are selective androgen receptor modulators. They are experimental compounds designed to interact with the androgen receptor while producing different activity patterns across androgen-responsive tissues.

Are all products in SARMs collections genuine SARMs?

No. MK-677 is a ghrelin-receptor agonist, Cardarine is a PPARδ agonist, and SR-9009 and SR-9011 are associated with REV-ERB research. They are commonly grouped with SARMs commercially but do not share the same primary molecular target.

Is MK-677 a SARM?

No. MK-677 Ibutamoren is more accurately classified as a growth-hormone secretagogue and ghrelin-receptor agonist.

Is Cardarine a SARM?

No. Cardarine GW-501516 is associated with PPARδ rather than the androgen receptor.

Is YK-11 a SARM?

YK-11 is commonly grouped with SARMs and has androgen-receptor partial-agonist activity. However, its steroidal structure and limited cellular evidence distinguish it from established non-steroidal SARMs.

Which SARMs have the strongest research evidence?

Evidence quality depends on the question being investigated. Ostarine and LGD-4033 have comparatively substantial published clinical research. RAD-140 has preclinical and specialised early clinical evidence. Several other compounds rely more heavily on cellular or animal models.

Are SARMs approved medicines?

No SARM has received general approval as a medicine for personal consumption.

Can SARMs be sold as dietary supplements in the UK?

The Food Standards Agency treats SARMs as unauthorised novel foods. They cannot lawfully be marketed as foods or dietary supplements.

Are SARMs prohibited in sport?

Yes. SARMs are prohibited under the WADA Prohibited List at all times.

What should a SARMs COA show?

A useful certificate should identify the compound, batch, testing date, analytical method, result and laboratory. Researchers should also determine whether the report evaluates identity, purity, quantity or another quality characteristic.

Does 99% purity mean a capsule contains the stated quantity?

Not necessarily. Purity and quantity are different measurements. A high-purity compound can still be present at a quantity different from the label claim.

Why are SARMs capsules sold in different strengths?

Capsule strength depends on the supplier’s specification and manufacturing format. Researchers should verify the stated strength, capsule count, batch information and supporting documentation rather than assuming all products use the same format.

Where can researchers compare SARMs UK products?

The BioPlex SARMs collection provides access to more than a dozen SARMs and related capsule-based research compounds, including RAD-140, LGD-4033, Ostarine, S-4, S-23, AC-262, ACP-105, YK-11, MK-677, RAD-150, SR-9009 and SR-9011.

Conclusion

The SARMs UK market contains a broader group of compounds than the scientific definition of a selective androgen receptor modulator.

Genuine SARMs such as RAD-140, LGD-4033, Ostarine, S-4, S-23, AC-262 and ACP-105 act through androgen-receptor pathways. YK-11 also interacts with the androgen receptor but has a steroidal structure and a specialised partial-agonist research profile.

MK-677, Cardarine, SR-9009 and SR-9011 are not genuine SARMs. They are grouped within the same commercial market because customers frequently search for and compare them together.

Understanding these distinctions supports more accurate research.

Evidence quality also differs materially between compounds. Ostarine and LGD-4033 have comparatively developed published research profiles. RAD-140 has documented receptor activity and specialised experimental research. Other products remain supported mainly by preclinical or cellular evidence.

No universal best SARM exists for every research objective. Compound selection should depend on the receptor pathway, experimental model, evidence quality, analytical requirements and endpoints being studied.

Researchers comparing SARMs for sale UK should also assess the supplier behind the product. Company identity, batch traceability, capsule specification, certificates of analysis, testing methods, responsible content and established customer support all contribute to supplier trust.

BioPlex Peptides supports this approach through UK capsule production to selected specifications, more than a dozen SARMs and related research products, clear compound information, testing support through Vanguard Laboratory and a growing library of scientific research articles.

The strongest SARMs guide is not the one making the biggest promises. It is the one that explains what the compounds are, where they differ, what the evidence shows and what remains unknown.

Continue Exploring...

Explore BioPlex SARMs Capsules and Research Compounds ⟶

Read Best SARMs for Muscle Growth: Top 3 Research Compounds Compared ⟶